金吾财讯 | 瑞士制药商诺华将向美国生物技术公司 Matchpoint Therapeutics支付高达10亿美元，用于开发治疗多种炎症疾病的口服药物。Matchpoint表示，将利用其技术开发阻断特定蛋白质活性的药物，以帮助降低引起炎症的信号的产生。该公司将利用诺华的资金领导研究和药物开发过程。如果诺华公司行使其对该项目进行独家授权的选择权，该制药商将拥有开发和商业化合作产生的所有产品的全球权利。Matchpoint 表示，它将获得高达 6000 万美元的预付款和研究资金，总潜在付款额高达 10 亿美元，其中包括期权行使费以及开发和商业里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.